RU2007149268A - ИСПОЛЬЗОВАНИЕ АНТИТЕЛ И MAdCAM ДЛЯ ЛЕЧЕНИЯ ЦЕЛИАКИИ И ТРОПИЧЕСКОЙ СПРУ - Google Patents

ИСПОЛЬЗОВАНИЕ АНТИТЕЛ И MAdCAM ДЛЯ ЛЕЧЕНИЯ ЦЕЛИАКИИ И ТРОПИЧЕСКОЙ СПРУ Download PDF

Info

Publication number
RU2007149268A
RU2007149268A RU2007149268/15A RU2007149268A RU2007149268A RU 2007149268 A RU2007149268 A RU 2007149268A RU 2007149268/15 A RU2007149268/15 A RU 2007149268/15A RU 2007149268 A RU2007149268 A RU 2007149268A RU 2007149268 A RU2007149268 A RU 2007149268A
Authority
RU
Russia
Prior art keywords
seq
antibody
mod
monoclonal antibody
madcam
Prior art date
Application number
RU2007149268/15A
Other languages
English (en)
Russian (ru)
Inventor
Гари Крейг БЕРДЖЕСС (GB)
Гари Крейг БЕРДЖЕСС
Original Assignee
Пфайзер Лимитед (GB)
Пфайзер Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Лимитед (GB), Пфайзер Лимитед filed Critical Пфайзер Лимитед (GB)
Publication of RU2007149268A publication Critical patent/RU2007149268A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
RU2007149268/15A 2005-07-08 2006-06-28 ИСПОЛЬЗОВАНИЕ АНТИТЕЛ И MAdCAM ДЛЯ ЛЕЧЕНИЯ ЦЕЛИАКИИ И ТРОПИЧЕСКОЙ СПРУ RU2007149268A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69745405P 2005-07-08 2005-07-08
US60/697,454 2005-07-08

Publications (1)

Publication Number Publication Date
RU2007149268A true RU2007149268A (ru) 2009-07-10

Family

ID=37491744

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007149268/15A RU2007149268A (ru) 2005-07-08 2006-06-28 ИСПОЛЬЗОВАНИЕ АНТИТЕЛ И MAdCAM ДЛЯ ЛЕЧЕНИЯ ЦЕЛИАКИИ И ТРОПИЧЕСКОЙ СПРУ

Country Status (15)

Country Link
US (1) US20100119517A1 (fr)
EP (1) EP1904103A2 (fr)
JP (1) JP2007016030A (fr)
KR (1) KR20080017088A (fr)
CN (1) CN101227923A (fr)
AR (1) AR055072A1 (fr)
AU (1) AU2006268045A1 (fr)
BR (1) BRPI0612645A2 (fr)
CA (1) CA2613017A1 (fr)
IL (1) IL188318A0 (fr)
MX (1) MX2008000129A (fr)
RU (1) RU2007149268A (fr)
TW (1) TW200740845A (fr)
WO (1) WO2007007145A2 (fr)
ZA (1) ZA200711163B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
LT2620450T (lt) * 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
CA2916283C (fr) 2015-01-09 2024-07-02 Pfizer Inc. Regime de dosage pour antagonistes de madcam
AU2018300189B2 (en) 2017-07-14 2025-05-15 Pfizer, Inc. Antibodies to MAdCAM
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof

Also Published As

Publication number Publication date
MX2008000129A (es) 2008-03-18
KR20080017088A (ko) 2008-02-25
WO2007007145A3 (fr) 2007-05-31
ZA200711163B (en) 2008-10-29
TW200740845A (en) 2007-11-01
CN101227923A (zh) 2008-07-23
WO2007007145A2 (fr) 2007-01-18
AR055072A1 (es) 2007-08-01
JP2007016030A (ja) 2007-01-25
US20100119517A1 (en) 2010-05-13
IL188318A0 (en) 2008-04-13
AU2006268045A1 (en) 2007-01-18
BRPI0612645A2 (pt) 2010-11-23
CA2613017A1 (fr) 2007-01-18
EP1904103A2 (fr) 2008-04-02

Similar Documents

Publication Publication Date Title
JP7143452B2 (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
JP7564853B2 (ja) 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
CN103382222B (zh) α-4-β-7异二聚体特异性拮抗剂抗体
JP2023061993A (ja) トランスサイレチン（ｔｔｒ）アミロイドーシスに対する抗体療法及びそのためのヒト由来抗体
CN104411719B (zh) 针对fel d1的人源抗体及其使用方法
RU2656181C1 (ru) Анти-pd-1-антитела, способ их получения и способ применения
TWI781130B (zh) 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
CN104540851B (zh) 抗tlr4抗体及其用途
RU2003100512A (ru) Антитела к человеческому мср-1
RU2011101969A (ru) Антитела к человеческому интерлейкину-20
JP2011509245A5 (fr)
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
JP2009532336A5 (fr)
WO2019005636A2 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
CN114524878B (zh) 一种双特异性抗体及其用途
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
CN107266571A (zh) 抗‑mcam抗体及相关使用方法
JP2010526028A5 (fr)
CN102933602A (zh) 人gdf8的抗体
TW201002344A (en) Monoclonal antibodies against the RGM a protein and uses thereof
CN117024592B (zh) 抗b7h3抗体及其用途
RU2009110154A (ru) АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
RU2003126168A (ru) Терапевтические связывающие молекулы
KR20140036267A (ko) Fc 수용체 결합 단백질

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090610

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20100519

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110110